Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13034822 | 1.00 | ALOX5AP (0.33) | ALOX5AP | |
| SCHEMBL18220553 | 0.72 | ALOX5AP (0.30) | ALOX5AP | |
| SCHEMBL3687706 | 0.69 | ALOX5AP (0.35) | ALOX5AP | |
| SCHEMBL13779596 | 0.69 | — | — | |
| SCHEMBL24587097 | 0.69 | SLC22A2 (0.30) | — | |
| SCHEMBL152170 | 0.69 | ALOX5AP (0.37) | ALOX5AP | |
| SCHEMBL11115020 | 0.68 | SLC22A2 (0.31) | — | |
| SCHEMBL22944870 | 0.68 | — | — | |
| SCHEMBL25641306 | 0.68 | ALOX5AP (0.32) | ALOX5AP | |
| SCHEMBL7120900 | 0.67 | ALOX5AP (0.32) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | ALOX5AP 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.